Security for the Pharmaceutical Industry: protecting IP, GxP production and clinical trials

Why the pharmaceutical industry is an extremely high-value target

Few sectors concentrate as many critical assets in a single physical and digital environment as the pharmaceutical industry. In a single plant coexist the intellectual property that defines the company's value — formulas, synthesis processes, registration dossiers and patents in formation — with regulated environments validated under Good Manufacturing Practices (GxP), and also with the operational technology (OT) that physically controls reactors, filling lines, heating, ventilation and air conditioning systems of clean rooms and product serialization. Each of these layers, on its own, would already be a relevant target. Together, they make pharma one of the most attractive profiles for organized cybercrime and sponsored industrial espionage.

The attackers' motivation varies according to the asset. Industrial espionage groups — often with state or competitor backing — seek the formula and the clinical research data that can anticipate the launch of a medication or nullify years of R&D investment. Ransomware operators seek the point of maximum pressure: stopping a validated production line means not only daily financial loss, but the risk of a shortage of essential medications, which increases the victim's willingness to pay. And sabotage actors seek to subtly alter process parameters, compromising entire batches without the deviation being noticed immediately.

The additional complication is regulatory. Systems that touch product quality — laboratory LIMS, manufacturing MES, quality management systems, qualified equipment — operate in a validated state. Any uncontrolled change in these systems requires revalidation, at significant cost and time. This creates a dangerous paradox: operational teams resist applying security patches for fear of invalidating the qualification, and the environment accumulates known vulnerabilities for months or years. Security must therefore be designed to coexist with validation, not against it.

The four threats that most affect pharma companies

1. Espionage of IP and clinical research data

The most valuable target is silent. Successful industrial espionage does not bring down systems or demand a ransom — on the contrary, it seeks to remain invisible for as long as possible, incrementally copying registration dossiers, pre-clinical and clinical trial results, process parameters and lists of strategic suppliers. The typical vector combines spear-phishing targeted at researchers and R&D directors, compromise of remote access credentials and lateral movement to the file servers and document management platforms where the IP resides. Because there is no operational noise, these attacks are frequently only discovered when a competitor launches a product suspected of being a copy.

2. Sabotage and ransomware in production OT (GxP)

When ransomware reaches the OT layer, the impact stops being just about data and becomes physical and regulatory. The encryption of MES servers and engineering workstations can paralyze filling lines, weighing and dispensing systems, and the serialization required for traceability. Worse than the stoppage is the contamination of the validated state: if the attacker altered parameters or if the recovery is done without rigor, batches may need to be discarded and entire systems revalidated. Deliberate sabotage is the most sophisticated version — altering temperature setpoints, mixing time or sterilization parameters subtly to compromise quality without triggering immediate alarms. In the supply chain, every connection with API suppliers, OT integrators and outsourced laboratories is a possible vector — through a malicious software update, poorly controlled permanent remote access or reused credentials.

3. Leakage of clinical-trial data

Clinical trials involve sensitive personal data of participants — a category that receives reinforced protection under the General Data Protection Law (LGPD). A leak of this data combines regulatory harm (notification to the ANPD, possible sanction), reputational harm and competitive harm, since trial results are also IP. The distributed nature of the studies, with research centers, CROs and electronic data capture platforms, multiplies the points where the information can escape.

OT/ICS segmentation: the most important structural defense

If there were a single priority investment for most pharma companies, it would be the segmentation between the operational technology and the corporate IT. The overwhelming majority of catastrophic incidents in industrial environments — including production stoppage by ransomware — do not begin in the OT. They begin in the office, in a phishing email or a leaked credential, and spread because there is no effective barrier between the two networks. Segmenting is cutting off that path.

Decripte adopts the reference model of the ISA/IEC 62443 standard, organizing the environment into zones (groupings of assets with equivalent security requirements) and conduits (the controlled communication paths between zones). At the highest layer is the corporate IT; below it, an industrial demilitarized zone (OT DMZ) that mediates all traffic between IT and OT; and in the lower layers, the supervision zones (SCADA, MES, historians) and the control zones (PLCs, instrumentation systems). No communication crosses zone boundaries without passing through an explicitly authorized and inspected conduit.

On top of the segmentation, we apply passive monitoring of the industrial protocols (such as Modbus, OPC UA, PROFINET and EtherNet/IP). Unlike IT, where you can install agents and perform active scans, OT requires an approach that does not interfere with the operation — sensors that only observe the mirrored traffic, learn the normal behavior of each asset and alert on deviations: an unexpected write command to a PLC, a new connection from an engineering workstation, a process parameter altered outside the maintenance window. This monitoring feeds Decripte's SOC 24x7 with visibility that most pharma companies never had over their own shop floor.

Anvisa/GxP and LGPD compliance without stalling security

The biggest cultural friction in pharmaceutical security is the false opposition between regulatory compliance and cybersecurity. Quality teams fear that security changes will invalidate qualifications; security teams see validation as an obstacle to fixing vulnerabilities. Decripte works exactly at this interface, translating security controls into the language of controlled change management, so that each action preserves the traceability and data integrity required by Good Manufacturing Practices.

In practice, this means that hardening, patching and configuration changes in GxP systems go through a documented change-control flow, with an assessment of the impact on validation, tests in a mirrored environment when applicable and complete recording. Data integrity follows the ALCOA+ principles — information that is Attributable, Legible, Contemporaneous, Original and Accurate, in addition to Complete, Consistent, Enduring and Available. The security controls that Decripte deploys reinforce precisely these attributes: access control and audit trail guarantee attributability; log immutability guarantees originality and endurance; and the detection of improper alteration protects accuracy.

On the personal-data axis, the LGPD applies strongly to clinical-trial and health data of the participants, which are sensitive personal data. This requires an adequate legal basis, minimization, technical controls proportional to the risk and a response plan capable of fulfilling the duty to communicate to the National Data Protection Authority (ANPD) and to the data subjects in the event of an incident that may cause relevant risk or harm. Decripte structures both the preventive controls and the notification runbook, so that the company does not discover its obligations in the middle of the crisis.

Red Team and threat hunting: finding the path before the attacker

Controls on paper do not prove resilience. The only way to know whether OT segmentation really prevents the pivot, whether the formula repository is in fact protected and whether the SOC would detect an intrusion is to simulate a real adversary. Decripte's Red Team conducts objective-oriented adversarial exercises: together with the leadership, we define what the 'crown jewel' would be — reaching a product's formula, reaching a production PLC, exfiltrating data from a clinical trial — and we try to attain it using the same tactics, techniques and procedures as an industrial spy or a ransomware group.

Unlike a one-off penetration test, the Red Team chains vectors: initial phishing, privilege escalation, lateral movement, detection evasion and, crucially, the attempt to cross the IT-OT boundary. Each barrier that stops the team becomes evidence of an effective control; each barrier crossed becomes a prioritized recommendation. Everything is conducted under strict rules of engagement, with absolute safeguards to never touch active production systems in a way that could affect product quality or patient safety.

In parallel, threat hunting proactively looks for signs of compromise that have escaped the automatic defenses. Instead of waiting for an alert, the analysts formulate hypotheses — 'an industrial spy would be exfiltrating R&D documents in small volumes to avoid detection' — and hunt for evidence in that direction: anomalous patterns of document access, unusual outbound connections, use of legitimate administration tools for malicious purposes. This work is especially vital against espionage, whose goal is precisely to go unnoticed.

The SOC 24x7 applied to the pharmaceutical environment

Detecting is not enough if the response is slow. Decripte's Security Operations Center (SOC) operates 24 hours a day, 7 days a week, correlating IT, OT, cloud and identity events in a single dashboard. For pharma companies, this means that an anomalous command to a PLC at three in the morning, an exfiltration attempt in the formula repository during a holiday, or a remote access by an integrator outside the authorized window trigger immediate investigation — not the next business morning.

The difference of a SOC specialized in industrial environments lies in the ability to interpret the context. An alert of a 'new network connection' means very different things in the office and in the control room. Decripte's SOC was structured to understand industrial protocols, recognize legitimate maintenance and validation patterns, and distinguish a normal quality operation from a malicious manipulation of parameters. This drastically reduces the false positives that, in OT, are especially costly.

When the SOC identifies a confirmed incident, containment begins within one hour, in accordance with Decripte's SLA. In pharmaceutical environments, fast and surgical containment is what separates a scare from a production stoppage with revalidation. The next section shows, in an anonymized real example, how this process happens end to end.

How we integrate everything: from the free assessment to the managed operation

A pharma company's security journey with Decripte does not begin with an extensive contract, but with visibility. The free Threat Management plan, available at decripte.com.br/intelligence-center, maps the real exposure of your operation — exposed assets, leaks associated with your domain, risk indicators — at no cost and no commitment. It is the most honest way to show where the company really is before proposing any investment.

From this assessment, the structuring advances in waves prioritized by risk: first the OT segmentation and the 24x7 monitoring, which cut off the most catastrophic paths; then the IP shielding and the GxP/LGPD compliance; next the adversarial validation with Red Team; and finally the continuous operation of vulnerability management and threat hunting. All delivered as a managed service, with the pharmaceutical company keeping its focus on what it does best — developing and producing medications — while Decripte takes care of security.

Anonymized real example: ransomware threatens a validated production line

How Decripte responds to an incident in a pharmaceutical environment

Incident response in pharma companies has a requirement that other sectors do not: containing and eradicating the attack without breaking the validated state of the GxP systems or compromising the integrity of regulatory data. Each step is designed for this.

1. 24x7 detection and triage: the SOC correlates IT, OT, identity and cloud events, confirms the incident and classifies criticality and potential impact on production and IP within minutes.
2. Surgical containment within 1 hour: we isolate what is compromised and close the critical conduits between IT and OT without shutting down production in progress, preserving the validated state of the regulated systems.
3. Forensic and trail preservation: we collect evidence while maintaining ALCOA+ data integrity and the audit trails required by GxP compliance, without destroying what auditors and the investigation will need.
4. Complete eradication: we map the full extent of the compromise, remove persistence, rotate exposed credentials and eliminate uncontrolled remote accesses of integrators and suppliers.
5. Validated recovery: we restore from immutable backups and prove the return to the qualified state, avoiding batch discard and unnecessary revalidation of the GxP systems.
6. Guided regulatory notification: we activate the communication runbook to the ANPD and the data subjects, when there is sensitive personal trial data involved, within the deadlines and responsibilities defined by the LGPD.
7. Post-incident structuring: we address the root cause with OT segmentation, access management and continuous monitoring, so that the same vector does not work again.
8. Adversarial validation: a subsequent Red Team confirms that the fixes really closed the attacker's path to the formulas and to production.

How Decripte structures the security of a pharma company

Structuring is organizing the defense in the order that most reduces risk, respecting the regulated reality of the environment. Decripte works on complementary pillars, all delivered as a managed service.

Recommended plans for Pharmaceutical Industry

Frequently asked questions

Sector terms

GxP

Set of regulatory Good Practices (such as GMP for manufacturing and GLP for laboratories) that govern the pharmaceutical industry. 'Validated GxP' systems operate in a qualified state, in which uncontrolled changes may require revalidation.

OT/ICS

Operational Technology and Industrial Control Systems — the set of PLCs, SCADA, MES and instrumentation that physically commands reactors, filling lines and serialization. Unlike IT, it requires security approaches that do not interfere with the operation.

ISA/IEC 62443

Family of international standards for the security of industrial automation and control systems. It organizes the environment into zones (groups of assets with equivalent requirements) and conduits (controlled communication paths between zones), the basis of OT segmentation.

ALCOA+

Data integrity principles required in regulated environments: data must be Attributable, Legible, Contemporaneous, Original and Accurate, in addition to Complete, Consistent, Enduring and Available. Well-designed security controls reinforce these attributes.

Red Team

Objective-oriented adversarial exercise that simulates a real attacker — an industrial spy or a ransomware group — to verify, in practice, whether the controls prevent access to the formulas, the trial data and the production OT.

SOC 24x7

Security Operations Center that monitors and responds to threats 24 hours a day, 7 days a week, correlating IT, OT, identity and cloud events to detect and contain incidents — at Decripte, with a containment SLA of up to 1 hour.